Home/Filings/4/0001714899-24-000061
4//SEC Filing

Watts Ryan J. 4

Accession 0001714899-24-000061

CIK 0001714899other

Filed

Feb 14, 7:00 PM ET

Accepted

Feb 15, 9:15 PM ET

Size

6.5 KB

Accession

0001714899-24-000061

Insider Transaction Report

Form 4
Period: 2024-02-13
Watts Ryan J.
DirectorPresident and CEO
Transactions
  • Sale

    Common Stock

    2024-02-13$17.29/sh9,589$165,794238,067 total
Holdings
  • Common Stock

    (indirect: See footnote)
    2,242,604
Footnotes (5)
  • [F1]Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
  • [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price
  • [F3]Includes 202,200 RSUs.
  • [F4]Reflects 25,759 shares previously disclosed as held indirectly; but have been determined to be held directly.
  • [F5]The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.

Issuer

Denali Therapeutics Inc.

CIK 0001714899

Entity typeother

Related Parties

1
  • filerCIK 0001724310

Filing Metadata

Form type
4
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 9:15 PM ET
Size
6.5 KB